Assessment of Serum Asprosin Level in Male Patients With Acne Vulgaris
1 other identifier
interventional
72
1 country
1
Brief Summary
Subject of interest is to evaluate serum level of asprosin in male patients with acne vulgaris, demonstrate the relation between acne vulgaris severity and level of asprosin in these patients \& the relation between metabolic syndrome in acne vulgaris and level of asprosin.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jul 2022
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 18, 2022
CompletedFirst Submitted
Initial submission to the registry
July 20, 2022
CompletedFirst Posted
Study publicly available on registry
July 22, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 18, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
January 18, 2023
CompletedJuly 22, 2022
July 1, 2022
6 months
July 20, 2022
July 20, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Assess serum asprosin level in male patients with acne vulgaris.
Assess serum asprosin level in male patients with acne vulgaris.
6 months
Study Arms (2)
case
ACTIVE COMPARATORcontrol
ACTIVE COMPARATORInterventions
assessment of serum asprosin by a commercially available double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) kit.
Eligibility Criteria
You may qualify if:
- Acne vulgaris male patients (\>18 years) will be included.
You may not qualify if:
- Age \<18 years.
- Females.
- Patients with other inflammatory skin disorders.
- Patients with associated systemic diseases.
- Current or previous treatment with isotretinoin in the last 3 month ,anti-inflammatory drugs, systemic antibiotics, androgen or anti androgen therapy, and steroid therapy).
- Patients known on treatment of diabetes, hypertension and dyslipidemia.
- Athletes.
- Patient refusal.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Sohag Universitylead
Study Sites (1)
Sohag University Hospital
Sohag, Egypt
Related Publications (4)
Rocha MA, Bagatin E. Adult-onset acne: prevalence, impact, and management challenges. Clin Cosmet Investig Dermatol. 2018 Feb 1;11:59-69. doi: 10.2147/CCID.S137794. eCollection 2018.
PMID: 29440921BACKGROUNDKovacs D, Fazekas F, Olah A, Torocsik D. Adipokines in the Skin and in Dermatological Diseases. Int J Mol Sci. 2020 Nov 28;21(23):9048. doi: 10.3390/ijms21239048.
PMID: 33260746BACKGROUNDNagpal M, De D, Handa S, Pal A, Sachdeva N. Insulin Resistance and Metabolic Syndrome in Young Men With Acne. JAMA Dermatol. 2016 Apr;152(4):399-404. doi: 10.1001/jamadermatol.2015.4499.
PMID: 26720707BACKGROUNDHong T, Li JY, Wang YD, Qi XY, Liao ZZ, Bhadel P, Ran L, Yang J, Yan B, Liu JH, Xiao XH. High Serum Asprosin Levels Are Associated with Presence of Metabolic Syndrome. Int J Endocrinol. 2021 Mar 2;2021:6622129. doi: 10.1155/2021/6622129. eCollection 2021.
PMID: 33747078BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- resident doctor at Dematology, Venereology and Andrology department at Sohag University Hospital
Study Record Dates
First Submitted
July 20, 2022
First Posted
July 22, 2022
Study Start
July 18, 2022
Primary Completion
January 18, 2023
Study Completion
January 18, 2023
Last Updated
July 22, 2022
Record last verified: 2022-07
Data Sharing
- IPD Sharing
- Will share